Acumen Pharmaceuticals: Conference Call to Discuss Results of Acumen’s Phase 1 INTERCEPT-AD Trial

Start Date:7/17/2023

Start Time:8:00 AM EDT

Duration:60 minutes

Abstract:

A Discussion of the Topline Results from Acumen’s Phase 1 INTERCEPT-AD Trial in Early Alzheimer’s Disease.

If you're already registered for the Acumen Pharmaceuticals: Conference Call to Discuss Results of Acumen’s Phase 1 INTERCEPT-AD Trial webcast, click below:

ALREADY REGISTERED?

Speakers

Daniel O’Connell

Chief Executive Officer

Acumen

Eric Siemers, MD

Chief Medical Officer

Acumen

Matt Zuga

Chief Financial Officer

Acumen

Steven DeKosky, MD

Deputy Director

McKnight Brain Institute at the University of Florida

Lawrence Honig, MD, PhD

Director

New York State Center of Excellence for Alzheimer's Disease at Columbia

First Name
Last Name
Email Address
Company
Time Zone

Already Registered? Technical Requirements System Check Port Troubleshooting